Curated News
By: NewsRamp Editorial Staff
December 23, 2025
Quantum BioPharma Completes Key Studies for MS Drug, Nears Clinical Trials
TLDR
- Quantum BioPharma's completion of oral dosing studies for Lucid-MS positions it ahead in developing a first-in-class MS treatment, potentially offering investors early advantage in a promising biotech sector.
- Quantum BioPharma completed 180-day chronic toxicity and toxicokinetic studies for Lucid-MS, supporting its IND application with the FDA and advancing toward Phase 2 clinical trials for multiple sclerosis.
- This milestone brings Quantum BioPharma's Lucid-MS closer to clinical trials, potentially offering new hope for people with multiple sclerosis by addressing the underlying mechanism of myelin degradation.
- Quantum BioPharma's Lucid-MS is a patented compound shown to prevent and reverse myelin degradation in preclinical models, representing a novel approach to treating multiple sclerosis.
Impact - Why it Matters
This development represents a significant advancement in multiple sclerosis treatment research, potentially offering new hope for the millions of people worldwide affected by this debilitating neurodegenerative disease. Multiple sclerosis currently has limited treatment options that primarily manage symptoms rather than addressing the underlying myelin degradation. Lucid-MS's novel approach of preventing and reversing myelin damage could represent a paradigm shift in MS therapy if clinical trials prove successful. For patients, this could mean more effective treatments that potentially halt or reverse disease progression rather than merely slowing it down. The progress toward Phase 2 trials indicates the treatment is moving closer to human testing, bringing it one step closer to potentially reaching patients who have limited options for addressing the fundamental pathology of their condition.
Summary
Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) has achieved a critical milestone in developing its promising multiple sclerosis treatment, Lucid-MS (Lucid-21-302). The company announced the completion of oral dosing in both 180-day chronic toxicity and toxicokinetic studies for this first-in-class therapeutic candidate. This significant step supports the planned Investigational New Drug (IND) application with the U.S. Food and Drug Administration and moves the program closer to clinical-stage development, specifically a Phase 2 clinical trial for people with multiple sclerosis. The news was disseminated on behalf of Quantum BioPharma Ltd. through the InvestorBrandNetwork.
The company, through its wholly owned subsidiary Lucid Psycheceuticals Inc., focuses on building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders. Lucid-MS represents their lead compound—a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, which is the underlying mechanism of multiple sclerosis. Beyond this flagship program, Quantum BioPharma maintains strategic interests through other ventures, including a 20.11% ownership stake in Unbuzzd Wellness Inc. (as of March 31, 2025) and a portfolio of strategic investments via its subsidiary FSD Strategic Investments Inc. For more details, readers can view the full press release via the provided hyperlink.
This development is part of a broader communication effort facilitated by InvestorWire (“IW”), a specialized platform within the Dynamic Brand Portfolio at IBN that provides advanced wire-grade press release syndication and corporate communications solutions. The platform ensures maximum reach through article and editorial syndication to over 5,000 outlets, enhanced press release features, and social media distribution to millions of followers. For ongoing updates, investors are directed to the company’s newsroom, accessible through the InvestorBrandNetwork.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Quantum BioPharma Completes Key Studies for MS Drug, Nears Clinical Trials
